NCT04678362 - TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 28, 2023

Study Completion Date

December 31, 2025

Conditions

Urothelial Carcinoma

Interventions

DRUG

Talazoparib + Avelumab

Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.

Trial Locations (14)

14000

ACTIVE_NOT_RECRUITING

Centre François baclesse, Caen

Unknown

RECRUITING

Institut de Cancérologie de l'Ouest, Angers

RECRUITING

CHU Jean Minjoz, Besançon

RECRUITING

Centre Jean Perrin, Clermont-Ferrand

RECRUITING

Centre George-François Leclerc, Dijon

RECRUITING

Centre Léon Bérard, Lyon

ACTIVE_NOT_RECRUITING

Hospices civils de Lyon, Lyon

NOT_YET_RECRUITING

Institut Paoli Calmettes, Marseille

RECRUITING

Institut de Cancérologie de l'Ouest, Nantes

RECRUITING

Centre Antoine Lacassagne, Nice

RECRUITING

Croix Saint-Simon Diaconesses, Paris

RECRUITING

Hopital Tenon, Paris

RECRUITING

Centre Eugène Marquis, Rennes

RECRUITING

IUCT, Toulouse